Sanchez Juan 4

What Happened

• Juan Sanchez, a member of Nuvectis Pharma's Board of Directors, received a grant of 35,000 shares of restricted common stock on 2026-06-11. The shares were granted at a $0.00 price (i.e., no cash paid) — total reported acquisition value $0.00. This is an equity award (compensation/board grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely — within required reporting window).
• Security: 35,000 restricted common shares granted at $0.00 per share (code A — award/grant).
• Vesting: Per footnote, the 35,000 shares vest in equal annual installments over three years beginning on the first anniversary of the grant, subject to continued board service.
• Holdings correction: Footnote notes inclusion of 230 restricted shares that were inadvertently omitted from Sanchez’s Form 3 filed on 2025-10-31.
• Shares owned after transaction: Not specified in the provided summary — see the filed Form 4 for total beneficial ownership reported.

Context

• This is a standard director compensation grant (restricted stock). Because the shares are restricted and vest over time, they are intended as long-term alignment rather than an immediate market purchase or sale.
• Awards at $0 are common for restricted stock grants and do not imply an outlay by the insider; they also do not by themselves signal buying/selling intent in the open market.